We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Provention Bio Inc | NASDAQ:PRVB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 24.98 | 25.04 | 24.90 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
OLDWICK, N.J., Oct. 29, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its third quarter 2019 financial results on Tuesday, November 5, 2019.
In connection with the earnings release, Provention's management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, November 5, 2019, to discuss the Company's financial results and provide a corporate update.
Conference Call Information
To access the call, please dial 1-877-870-4263 (domestic) or 1-412-317-0790 (international) five minutes prior to the start time and ask to be connected to the "Provention Bio Call". An audio webcast will also be available in the "Events and Webcasts" page in the Investors page of the Company's website, www.proventionbio.com. An archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.
About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a clinical-stage biopharmaceutical company leveraging a transformational drug development strategy that is focused on the prevention or interception of immune-mediated disease. Provention's mission is to in-license, transform and develop therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases including: type 1 diabetes (T1D), Crohn's disease, celiac disease, and lupus. Provention's diversified portfolio includes advanced-stage product development candidates that have undergone clinical testing by other companies.
Investors:
Sam Martin, Argot Partners
sam@argotpartners.com
212-600-1902
Media:
David Rosen, Argot Partners
david.rosen@argotpartners.com
212-600-1902
View original content to download multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-report-third-quarter-2019-financial-results-and-host-conference-call-on-tuesday-november-5-2019-300946841.html
SOURCE Provention Bio, Inc.
Copyright 2019 PR Newswire
1 Year Provention Bio Chart |
1 Month Provention Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
